Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have revolutionized therapy for chronic myeloid leukemia (CML), paving the way for clinical development in other diseases. Despite success, targeting leukemic stem cells and overcoming drug resistance remain challenges for curative cancer therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Bencomo-Alvarez, Alfonso E., Rubio, Andres J., Olivas, Idaly M., Gonzalez, Mayra A., Ellwood, Rebecca, Fiol, Carme Ripoll, Eide, Christopher A., Lara, Joshua J., Barreto-Vargas, Christian, Jave-Suarez, Luis F., Nteliopoulos, Georgios, Reid, Alistair G., Milojkovic, Dragana, Druker, Brian J., Apperley, Jane, Khorashad, Jamshid S., Eiring, Anna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952820/
https://www.ncbi.nlm.nih.gov/pubmed/33712704
http://dx.doi.org/10.1038/s41388-021-01732-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952820/
https://www.ncbi.nlm.nih.gov/pubmed/33712704
http://dx.doi.org/10.1038/s41388-021-01732-6

Ejemplares similares